A newly floated US biotech company has achieved a valuation of $2.2bn. Good for them, you say? You might not think that if you’re a GlaxoSmithKline (LSE: GSK) shareholder and you learn who Axovant got its sole product from — and what it paid!
How GlaxoSmithKline plc Gave Away $2bn!
VIDEO: One Fool puts GlaxoSmithKline plc (LON:GSK) under the spotlight.
Posted by
Published Owain is a magpie of the investing world -- and not because he gets into a flap. Almost any style of investing might suit him, depending on the bigger picture, and he's held all sorts of companies. Paraphrasing Keynes, he says: “When the market changes, I change my mind -- what do you do?”
That said, Owain is usually a buyer of equities, where he prefers lightly geared, modestly rated companies, and is increasingly on the lookout for Buffett-style intangible quality. He aspires to buy-and-hold: his best investment ideas are worth much more than he sold them for. Then again, his worst investment went bust due to management fraud!
The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.
